ArticleACS omega2026
Gum Arabic-Stabilized 8‑Prenylchrysin Nanoemulsion with Enhanced Bioaccessibility and Anti-Inflammatory Effect.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, we developed 8-prenylchrysin (PC), a prenylated chrysin derivative with potent anti-inflammatory activity. In the present study, a gum arabic-stabilized nanoemulsion (NE) was developed to enhance the gastrointestinal bioaccessibility (BA) and delivery performance of PC. The formulated PC-encapsulated emulsion systems (PC-ESs) showed a homogeneous droplet size distribution of 38.5 ± 0.05 nm, an encapsulation efficiency reaching 99.4 ± 0.06%, and favorable colloidal stability over 30 days of storage. Simulated gastrointestinal digestion revealed that PC-ES substantially increased the transfer of PC into the micellar fraction compared with unformulated PC, indicating improved BA. Furthermore, PC-ES retained its anti-inflammatory effect by attenuating lipopolysaccharide-stimulated inflammatory responses in murine RAW264.7 macrophages. Collectively, these findings demonstrate that the GA-based NE provides an effective approach for enhancing the gastrointestinal BA and practical utilization of PC.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.